Screener
BioMarin Pharmaceuticals BMRN Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.1%-3.4pp | 76.5%-2.9pp | 77.7%-1.9pp | 81.3%+2.5pp | 79.6%-0.3pp | |
| Returns | ||||||
| Return on invested capital | 1.5%-9.2pp | 5.2%-3.3pp | 6.6%-1.4pp | 8.8%+3.6pp | 10.7%+6.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×-0.1× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.4×-3.2× | 5.8×+0.3× | 5.2×-0.1× | 4.8×+0.6× | 5.6×+2.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.7×+0.6× | 0.2×+0.1× | 0.1×+0.1× | 0.1×0.0× | 0.1×-0.2× | |
| Net debt / EBITDA | 9.5×+10.2× | -3.8×-3.1× | -1.2×+0.3× | -0.9×-0.8× | -0.7×-2.4× | |
| Per Share | ||||||
| Book value per share | $32.51+6.3% | $31.43+6.6% | $30.84+7.2% | $31.54+14.9% | $30.58+16.0% | |
| Valuation | ||||||
| Market capitalization | $11.58B-0.6% | $10.86B-19.4% | $11.42B-8.9% | $10.4B-22.3% | $10.49B-32.9% | |
| Price / sales | 3.4×-0.4× | 3.4×-1.2× | 3.5×-0.8× | 3.4×-1.5× | 3.4×-2.6× | |
| Price / book | 1.8×-0.1× | 1.7×-0.6× | 1.9×-0.3× | 1.7×-0.8× | 1.7×-1.2× | |
| EV / EBITDA | 42.6×+29.8× | 21.1×+2.8× | 20×0.0× | 14×-15.6× | 11.5×-32.1× |
FAQ
- What are BioMarin Pharmaceuticals's profit margins?
- BioMarin Pharmaceuticals (BMRN) runs a 76.1% gross margin and a 19.9% operating margin, with a 16.8% net margin.
- Where do BioMarin Pharmaceuticals's ratios come from?
- Every ratio is computed from BioMarin Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
